Tyzzerella nexilis strains enriched in mobile genetic elements are involved in progressive multiple sclerosis
- PMID: 39341204
- DOI: 10.1016/j.celrep.2024.114785
Tyzzerella nexilis strains enriched in mobile genetic elements are involved in progressive multiple sclerosis
Erratum in
-
Tyzzerella nexilis strains enriched in mobile genetic elements are involved in progressive multiple sclerosis.Cell Rep. 2025 Jan 28;44(1):115228. doi: 10.1016/j.celrep.2024.115228. Epub 2025 Jan 7. Cell Rep. 2025. PMID: 39772393 No abstract available.
Abstract
Multiple sclerosis (MS) is an autoimmune-demyelinating disease with an inflammatory pathology formed by self-reactive lymphocytes with activated glial cells. Progressive MS, characterized by resistance to medications, significantly differs from the non-progressive form in gut microbiome profiles. After confirming an increased abundance of "Tyzzerella nexilis" in various cohorts of progressive MS, we identified a distinct cluster of T. nexilis strains enriched in progressive MS based on long-read metagenomics. The distinct T. nexilis cluster is characterized by a large number of mobile genetic elements (MGEs) and a lack of defense systems against MGEs. Microbial genes for sulfate reduction and flagella formation with pathogenic implications are specific to this cluster. Moreover, these flagellar genes are encoded on MGEs. Mono-colonization with MGE-enriched T. nexilis made germ-free mice more susceptible to experimental autoimmune encephalomyelitis. These results indicate that the progression of MS may be promoted by MGE-enriched T. nexilis with potentially pathogenic properties.
Keywords: CP: Microbiology; Tyzzerella nexilis; experimental autoimmune encephalomyelitis; flagella; gut microbiome; long-read metagenomics; mobile genetic elements; multiple sclerosis; sulfate reduction.
Copyright © 2024 The Author(s). Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests T.Y. served on the scientific advisory board of Biogen Japan, Ltd., and received support for research and clinical trials from Sanofi K.K., Chugai Pharmaceutical, Co., Ltd., UCB Japan Co., Ltd., Biogen Japan, Ltd., Chiome Bioscience, Inc., Novartis Pharma K.K., and Mebix, Inc.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
